Home›Clinical trials›Connecticut

GLP-1 clinical trials in Connecticut: 12 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

12 GLP-1 clinical trials are recruiting at 15 sites in 6 cities across Connecticut. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Connecticut

  1. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    2 sites in Connecticut

    • Connecticut Gastroenterology Clinical Research Foundation, Bristol. 833-602-2368
    • Yale University School of Medicine, New Haven. 833-602-2368

    NCT06632444 on ClinicalTrials.gov. See whether you qualify.

  2. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Eli Lilly and Company plans to enroll 125 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    2 sites in Connecticut

    NCT06672549 on ClinicalTrials.gov. See whether you qualify.

  3. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Kailera plans to enroll 1,200 participants.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Connecticut

    • Kailera Clinical Site, Hamden
    • Kailera Clinical Site, Stamford

    NCT07284979 on ClinicalTrials.gov. See whether you qualify.

  1. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in Connecticut

    • Connecticut Gastroenterology Clinical Research Foundation, Bristol. 833-602-2368

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

  2. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Eli Lilly and Company plans to enroll 150 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in Connecticut

    • Stamford Therapeutics Consortium, Stamford

    NCT06672939 on ClinicalTrials.gov. See whether you qualify.

  3. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Eli Lilly and Company plans to enroll 800 participants.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Connecticut

    NCT07153471 on ClinicalTrials.gov. See whether you qualify.

  4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Eli Lilly and Company plans to enroll 4,500 participants.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Connecticut

    • Medical Research Center of Connecticut, Hamden

    NCT07165028 on ClinicalTrials.gov. See whether you qualify.

  5. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. AstraZeneca plans to enroll 1,200 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Connecticut

    • Research Site, Bridgeport

    NCT07662213 on ClinicalTrials.gov. See whether you qualify.

  6. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Eli Lilly and Company plans to enroll 1,481 participants.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Connecticut

    • Stamford Therapeutics Consortium, Stamford

    NCT06143956 on ClinicalTrials.gov. See whether you qualify.

  7. Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

    Phase 2. Yale University plans to enroll 54 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 1 diabetes lower blood sugar and lose weight.

    Who can join. Adults 18 to 30, have type 1 diabetes, BMI 27+.

    1 site in Connecticut

    • Yale Pediatric Diabetes Center, Adult and Children's Progam, New Haven

    NCT06411210 on ClinicalTrials.gov. See whether you qualify.

The other 2 studies recruiting in Connecticut

  1. Multi-Site Trial of Tirzepatide for Smoking Cessation

    Phase 2. University of Southern California plans to enroll 300 participants.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people quit smoking.

    Who can join. Adults 21 to 65, are trying to quit smoking, BMI 25+.

    1 site in Connecticut

    NCT07602699 on ClinicalTrials.gov. See whether you qualify.

  2. Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

    Phase 1. Yale University plans to enroll 10 participants.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18+, have alcohol use disorder, BMI 27+.

    1 site in Connecticut

    • Yale School of Medicine, New Haven

    NCT07223983 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
Written and edited by John SamarasAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.